Physician profile
Ester Caballero
NPI 1548744642
$7,186.67
in general payments reported to CMS, 2019-2025
24 companies · $3,573 in 2025
The $3,573 reported for 2025 was more than what 98% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $78.96 · 2022: $49.89 · 2023: $1,988 · 2024: $1,496 · 2025: $3,573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,445 · Travel and Lodging: $2,612.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,445.34 |
| Travel and Lodging | $2,612.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,914.47 | 2021-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Cvrx, INC. | $1,283.18 | 2024-2025 | Barostim Neo System |
| E.R. Squibb & Sons, L.L.C. | $399.16 | 2022-2025 | Camzyos |
| United Therapeutics Corporation | $195.61 | 2023-2025 | Tyvaso, Tyvaso |
| Takeda Pharmaceuticals U.S.A., INC. | $175.27 | 2023-2025 | Livtencity |
| Actelion Pharmaceuticals US, INC. | $165.14 | 2021-2025 | Uptravi, Opsumit |
| Daiichi Sankyo INC. | $141.78 | 2023-2025 | Injectafer |
| Abiomed | $132.95 | 2024-2025 | Impella |
| Kestra Medical Technology Services, INC. | $111.19 | 2025 | Assure Wcd |
| Merck Sharp & Dohme LLC | $105.67 | 2024-2025 | Verquvo, Winrevair, Dificid |
| Mallinckrodt Hospital Products INC. | $104.66 | 2024 | Terlivaz |
| Irhythm Technologies, INC. | $93.64 | 2024 | Zio Monitor, Zio Xt Patch |
| Atricure, INC. | $64.96 | 2025 | Atriclip Laa Exclusion System, Epi-Sense Guided Coagulation System With Visitrax |
| Pfizer INC. | $62.45 | 2021-2025 | |
| Bridgebio Pharma, INC. | $33.99 | 2025 | Attruby |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $31.79 | 2024-2025 | |
| One Lambda, INC. | $29.54 | 2025 | |
| Endotronix, INC. | $27.36 | 2025 | Cordella Pulomonary Artery Pressure Sensor |
| Impulse Dynamics (USA) INC. | $27.05 | 2023 | Optimizer |
| Novartis Pharmaceuticals Corporation | $20.37 | 2023 | |
| Astellas Pharma US INC | $20.13 | 2025 | Cresemba |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.78 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.88 | 2024 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $13.65 | 2023 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ester Caballero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.